Raily Aesthetic Medicine International Holdings Limited (2135) AI Stock Analysis

• Market Cap: HK$66.29M
• Dividend Yield: N/A
• Average Volume (3M): 591.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: 3.14%
• EPS Growth: -57.92%
• Country: HK
• Employees: 290
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 557,077,330
• 10 Day Avg. Volume: 482,266
• 30 Day Avg. Volume: 591,441
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by the company's weak financial performance, characterized by persistent losses and increasing leverage. Technical analysis provides a slightly better outlook with neutral indicators, but valuation remains poor due to negative earnings and lack of dividends. The absence of earnings call data and corporate events means these factors do not influence the score.

Raily Aesthetic Medicine International Holdings Limited Business Overview & Revenue Model

Company Description

Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services. The company operates through three segments: Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipment Products. Its services include aesthetic surgery services, including aesthetic surgical procedures performed on various parts of the face or body; minimally invasive aesthetic services, primarily comprising aesthetic injection procedures; aesthetic dermatology services, such as various aesthetic energy-based procedures; and aesthetic medical management consulting services. The company also offers aesthetic dental services, including orthodontics, and dental implant and whitening; and trades in medical equipment. In addition, it sells surgical implants and aesthetic medical skincare products. The company owns and operates a network of four private for-profit aesthetic medical institutions in Zhejiang and Anhui Province, the People's Republic of China. It serves individual retail clients and aesthetic medical institutions. The company was founded in 2008 and is headquartered in Hangzhou, the People's Republic of China. Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.

How the Company Makes Money

Raily Aesthetic Medicine International Holdings Limited generates revenue primarily through the provision of aesthetic medical services and the sale of related products. The key revenue streams include fees charged for various aesthetic treatments such as laser therapies, injectables, and skincare procedures. The company also earns income by selling skincare products and cosmetics associated with its treatments. Strategic partnerships with cosmetic product manufacturers and distribution channels enhance its market reach and contribute to its earnings. Additionally, Raily Aesthetic Medicine may engage in training and consulting services for professionals in the aesthetic industry, further diversifying its revenue base.

Raily Aesthetic Medicine International Holdings Limited Financial Statement Overview

Summary

The company faces operational and financial challenges, with declining revenue, negative net profit margins, and negative free cash flow. The balance sheet shows moderate leverage but declining equity, while cash flow generation is a concern.

Income Statement

The company has experienced declining revenue over the past few years, with a slight increase in the latest year. Gross profit margins have decreased, and the net profit margin is negative, indicating ongoing losses. Revenue growth is inconsistent, and EBIT and EBITDA margins are negative, reflecting operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, which indicates manageable leverage. However, the equity ratio has been decreasing, suggesting a potential decline in financial stability. Return on equity is negative, reflecting ongoing losses.

Cash Flow

The company has faced significant challenges in generating positive free cash flow, with a negative free cash flow growth rate. The operating cash flow to net income ratio is weak, indicating inefficiencies in converting income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.34M	189.38M	164.52M	188.37M	164.54M
Gross Profit	71.41M	71.49M	66.78M	69.69M	80.17M
EBITDA	-34.29M	-6.03M	3.89M	-6.00M	25.95M
Net Income	-59.21M	-32.46M	-15.91M	-17.69M	4.25M
Balance Sheet
Total Assets	249.92M	273.60M	302.65M	344.73M	272.33M
Cash, Cash Equivalents and Short-Term Investments	28.87M	39.79M	78.78M	111.22M	165.39M
Total Debt	56.37M	51.78M	48.22M	67.45M	32.19M
Total Liabilities	154.41M	141.01M	136.77M	162.37M	85.58M
Stockholders Equity	104.13M	138.12M	166.08M	178.22M	185.87M
Cash Flow
Free Cash Flow	-38.59M	-10.00M	-21.13M	-18.25M	5.56M
Operating Cash Flow	6.01M	8.02M	-2.27M	-2.47M	14.16M
Investing Cash Flow	-12.70M	-26.14M	558.00K	-82.45M	-13.34M
Financing Cash Flow	19.43M	-10.48M	-25.65M	11.97M	92.67M

Raily Aesthetic Medicine International Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2135, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 13.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2135.

Raily Aesthetic Medicine International Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2373	76 Outperform	HK$8.26B	32.54	26.24%	1.47%	17.69%	5.37%
8357	60 Neutral	HK$109.82M	―	-10.31%	―	-11.68%	-71.01%
8161	58 Neutral	HK$18.30M	2.27	105.83%	―	-8.48%	―
8307	56 Neutral	HK$86.49M	―	-44.60%	―	-8.20%	-10.39%
Sector *	51 Neutral	$7.86B	-0.26	-41.41%	2.22%	22.87%	-2.01%
2135	46 Neutral	HK$66.29M	―	-48.87%	―	3.14%	-57.92%
8437	41 Neutral	HK$10.32M	―		―	14.64%	-81.95%

Raily Aesthetic Medicine International Holdings Limited Corporate Events

Raily Aesthetic Medicine Announces Deemed Disposal of Subsidiary Equity

Raily Aesthetic Medicine International Holdings Limited announced a deemed disposal of equity interest in a subsidiary through an investment agreement with two investors. The transaction involves a capital injection by the investors, resulting in a significant reduction of Hangzhou Raily’s equity in the Target Company from 100% to 30%. This move is part of a strategy to reduce accumulated losses and improve the financial position of the subsidiary. The transaction is classified as a discloseable transaction under Hong Kong’s Listing Rules, requiring an announcement but not shareholder approval.

Raily Aesthetic Medicine Enhances Governance with New Nomination Committee

Raily Aesthetic Medicine International Holdings Limited has established a nomination committee to identify and recommend candidates for the board of directors, oversee board performance evaluations, and develop nomination guidelines. This move is expected to enhance the governance structure of the company, ensuring compliance with applicable laws and regulations, and potentially strengthening its market position by promoting diversity and independence within its board.

Raily Aesthetic Medicine Secures Unanimous Shareholder Support at 2025 AGM

Raily Aesthetic Medicine International Holdings Limited announced that all proposed resolutions at its 2025 Annual General Meeting were approved by shareholders. Key resolutions included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates for share issuance and repurchase. This unanimous approval reflects strong shareholder support and may positively impact the company’s strategic decisions and market positioning.